Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Skip to content

Aspen Institute Italia Award – Award Ceremony

  • Rome
  • 27 September 2023

        The 8th Aspen Institute Italia Award for scientific research and collaboration between Italy and the United States went to a study on a new synthetic protein that promises to alleviate neuropathic pain. The ceremony and panel, with the participation of several of the winning scientists, offered an opportunity to discuss the future prospects of biomedicine. 

        The 2023 Award winners: Henry M. Colecraft, Rajesh Khanna, Anna Moroni, Gerhard Thiel, Raffaella Tonini, Massimo Pasqualetti

        The results of scientific research in this field make it possible to envisage the gradual replacement of chemistry’s contribution to medicine with a new approach based on biology and personalized treatment. The main challenge is that of sustainability.

        Extensive investments by industry and the growing productivity of clinical studies are evidence of the progress the sector has made and potential future developments. Nevertheless, to be successful, this revolution calls for more effective collaboration among all actors concerned. This is an especially important aspect for a country such as Italy, whose pharmaceutical sector contributes a full 2% of GDP, half of which is generated by foreign capital companies. Maintaining the country’s appeal to international firms involves a series of targeted concerns, starting with intellectual property rights and the importance of training and retaining highly qualified human capital.

        That is where the role of private operators working in treatment, hospital research and training comes in. These can make a major contribution to sector innovation in terms of disseminating new therapies as well as focusing training programs on making the best use of technology in medicine.

        To that end, Italy must strive to adequately promote the contribution of private operators within the National Health Service, where tariff freezes threaten to stall innovation. Furthermore, such efforts must be part of a broad-based program. Various European countries have already drafted national Life Sciences plans capable of permitting, over time, the organization of activities in the field of medicine that produce significant, concrete results. Spain’s preeminence in the area of clinical studies highlights such opportunities.

        Panel debate: “The future of biomedicine”. Mary Adjepong, Alberto Quadrio Curzio, Francesco Leopardi Dittaiuti, Barbara Carfagna
        Giulio Tremonti, Giorgio Palù, Giovanni Rezza
        Grazie Francescato, Giuseppe Fedegari, Giovanna dell’Erba